Cargando…

Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy

To overcome unsatisfactory results of classical low-dose cytarabine (LDAC) of cytarabine ≤20 mg twice daily (BID) subcutaneously for 10 days for patients with elderly acute myeloid leukemia (eAML), we evaluated a modified LDAC (mLDAC) of cytarabine 20 mg/m(2) BID subcutaneously plus etoposide 50 mg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Seung-Hwan, Cho, Byung-Sik, Park, Sung-Soo, Cho, Sung-Yeon, Jeon, Young-Woo, Yoon, Jae-Ho, Yahng, Seung-Ah, Lee, Sung-Eun, Lee, Dong-Gun, Eom, Ki-Seong, Kim, Yoo-Jin, Lee, Seok, Min, Chang-Ki, Cho, Seok-Goo, Kim, Dong-Wook, Lee, Jong-Wook, Min, Woo-Sung, Kim, Hee-Je
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814177/ https://www.ncbi.nlm.nih.gov/pubmed/29464037 http://dx.doi.org/10.18632/oncotarget.23629

Ejemplares similares

The impact of novel therapeutic agents before and after frontline autologous stem cell transplantation in patients with multiple myeloma
por: Min, Chang-Ki, et al.
Publicado: (2013)

Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
por: Kwag, Daehun, et al.
Publicado: (2022)

Second Primary Glioblastoma Multiforme Following Autologous Hematopoietic Stem Cell Transplantation in a Patient with Acute Myelogenous Leukemia
por: Kim, Eun-Oh, et al.
Publicado: (2011)

The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease
por: Min, Gi-June, et al.
Publicado: (2021)

Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome
por: Han, Seunghoon, et al.
Publicado: (2015)

Prognostic Impacts of D816V KIT Mutation and Peri-Transplant RUNX1–RUNX1T1 MRD Monitoring on Acute Myeloid Leukemia with RUNX1–RUNX1T1
por: Cho, Byung-Sik, et al.
Publicado: (2021)

SOCS1 and SOCS3 are expressed in mononuclear cells in human cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation
por: Shin, Seung-Hwan, et al.
Publicado: (2015)

Treatment for relapsed acute promyelocytic leukemia: what is the best post-remission treatment?
por: Min, Gi-June, et al.
Publicado: (2022)

Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts
por: Yahng, Seung-Ah, et al.
Publicado: (2016)

Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission
por: Yoon, Jae-Ho, et al.
Publicado: (2016)

Impact of Epstein-Barr Virus on Peripheral T-Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-Cell Lymphoma
por: Kim, Tong-Yoon, et al.
Publicado: (2022)

Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types
por: Yoon, Jae-Ho, et al.
Publicado: (2017)

Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents
por: Lee, Sung-Eun, et al.
Publicado: (2018)

High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study
por: Yoon, Jae-Ho, et al.
Publicado: (2017)

Clinical manifestations of autoimmune disease-related non-Hodgkin lymphoma: a Korean single-center, retrospective clinical study
por: Jeon, Young-Woo, et al.
Publicado: (2016)

Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia
por: Yoon, Jae-Ho, et al.
Publicado: (2017)

Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma
por: Batsukh, Khishigjargal, et al.
Publicado: (2017)

A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)
por: Park, Silvia, et al.
Publicado: (2022)

Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification
por: Kim, Tong-Yoon, et al.
Publicado: (2022)

Circulating CD3(+)CD4(+)CD161(+) Cells Are Associated with Early Complications after Autologous Stem Cell Transplantation in Multiple Myeloma
por: Lee, Sung-Eun, et al.
Publicado: (2018)

Bone Marrow Plasma Cell Assessment before Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
por: Lee, Sung-Eun, et al.
Publicado: (2014)

Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients
por: Yoon, Jae-Ho, et al.
Publicado: (2015)

Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients
por: Kim, Tong-Yoon, et al.
Publicado: (2022)

Expression of SOCS1 and SOCS3 genes in human graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
por: Lee, Tae Hyang, et al.
Publicado: (2013)

Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy
por: Yoon, Jae-Ho, et al.
Publicado: (2019)

Predictive Role of Circulating Immune Cell Subtypes Early after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia
por: Kim, Tae Woo, et al.
Publicado: (2018)

Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation
por: Lee, Sung-Eun, et al.
Publicado: (2019)

Low frequency of CD3(+)CD4(+)CD161(+) T cells correlates with the occurrence of infections in refractory/relapsed multiple myeloma patients receiving lenalidomide plus low-dose dexamethasone treatment
por: Lee, Sung-Eun, et al.
Publicado: (2018)

Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia in first salvage
por: Yoon, Jae‐Ho, et al.
Publicado: (2019)

Improved survival outcomes and restoration of graft‐vs‐leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia
por: Cho, Byung‐Sik, et al.
Publicado: (2019)

Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia
por: Yoon, Jae-Ho, et al.
Publicado: (2019)

A Case Report of the Second de Novo Acute Myeloid Leukemia (AML) Following Allogeneic Stem Cell Transplantation in a Patient with the First AML
por: Cho, Byung-Sik, et al.
Publicado: (2010)

Differential effects of donor lymphocyte infusion upon treatment response and GVHD according to relapse level and donor sources in patients with myelodysplastic syndrome
por: Park, Silvia, et al.
Publicado: (2021)

Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis
por: Yoon, Jae-Ho, et al.
Publicado: (2020)

HLA-mismatched donor and high ferritin level showed poor clinical outcomes after allogeneic hematopoietic cell transplantation in patients with advanced myelofibrosis
por: Yoon, Jae-Ho, et al.
Publicado: (2020)

Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia: high-risk features for early and long-term mortality
por: Yoon, Jae-Ho, et al.
Publicado: (2022)

Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin’s lymphoma
por: Jeon, Young-Woo, et al.
Publicado: (2019)

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
por: Jeon, Young‐Woo, et al.
Publicado: (2019)

Dynamic changes in physical function during intensive chemotherapy affect transplant outcomes in older adults with AML
por: Min, Gi-June, et al.
Publicado: (2023)

Topotecan-Based Combination Chemotherapy in Patients with Transformed Chronic Myelogenous Leukemia and Advanced Myelodysplastic Syndrome
por: Park, Soo Jeong, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_srrjq2ufh3cj79o6ftkk1ro7c3